000			03039cam a2200277zu 4500
001			88805533
003			FRCYB88805533
005			20251020123430.0
006			m o d
007			cr un
008			251020s2007 fr | o|||||0|0|||eng d
020			_a9782868839626
035			_aFRCYB88805533
040			_aFR-PaCSA _ben _c _erda
100	1		_aZimmermann, Richard
245	0	1	_aNuclear Medicine _bRadioactivity for Diagnosis and Therapy _c['Zimmermann, Richard']
264		1	_bEDP Sciences _c2007
300			_a p.
336			_btxt _2rdacontent
337			_bc _2rdamdedia
338			_bc _2rdacarrier
650		0	_a
700	0		_aZimmermann, Richard
856	4	0	_2Cyberlibris _uhttps://international.scholarvox.com/netsen/book/88805533 _qtext/html _a
520			_aNuclear medicine is a specialized medical field based on the application of radiopharmaceuticals, i.e. drugs associated to radioactivity, for diagnosis or therapeutic purposes. In the past fifty years, nuclear medicine has progressed in such a way that it is now a major tool in hospitals. Nowadays, this technology enables to better detect, observe and describe diseases, and also to improve treatments. Cancer therapy is the main application of this speciality. Once injected to the patient, the radiopharmaceutical drug aims selectively at the tumoral cells, including the metastases, settles there and emits radiation. Depending on the type of radiation, the drug will either help to identify the cells or to destroy them. Recent breakthroughs in this technology bring new perspectives to oncology, haematology and neurology. At the same time, since the beginning of the 21st century nuclear medicine has also benefited from a double revolution in terms of imaging technology. On the one hand, the Positron Emission Tomography (PET) made a real impact with a polyvalent imaging drug called FDG. On the other hand, a new tool combining functional and morphological imaging (PET-CT) was very recently made available to the medical community. This scientific book aims to introduce nuclear medicine to a larger audience, pointing out, among other things, the difficulties both physicians and patients meet when trying to access new technologies. There are still some issues to overcome, but recent scientific breakthroughs bring great hopes for patients in the near future. Richard Zimmermann is an organic chemistry PhD (Strasbourg, France) with a post-doctoral experience at Georgetown University (Washington DC, USA). He has spent the past twenty years working in the pharmaceutical industry throughout Europe (France, Germany, the Netherlands, Switzerland) mainly in research and development in fields such as cardiology, immunology, gastro-enterology and finally neurology until 1999, when he became head of the French-based Nuclear Medicine Research and Development Department of an international pharmaceutical group. Since 2004, he is also in charge of the Development Programme of the PET technology for this same company.
999			_c1554195 _d1554195